Cargando…
QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
CONTEXT: Atorvastatin (ATV) and QiShenYiQi pills (QSYQ), a Chinese patent medicine, are often co-prescribed to Chinese cardiovascular patients. The effects of QSYQ on the pharmacokinetics of ATV have not been studied. OBJECTIVE: We investigated the influence of QSYQ on the pharmacokinetics of ATV an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745373/ https://www.ncbi.nlm.nih.gov/pubmed/35001796 http://dx.doi.org/10.1080/13880209.2021.2021949 |
_version_ | 1784630329648087040 |
---|---|
author | Ding, Congyang Li, Yajing Li, Xiao Meng, Lu Fu, Ran Wang, Xiaonan Li, Ying Ma, Yinling Dong, Zhanjun |
author_facet | Ding, Congyang Li, Yajing Li, Xiao Meng, Lu Fu, Ran Wang, Xiaonan Li, Ying Ma, Yinling Dong, Zhanjun |
author_sort | Ding, Congyang |
collection | PubMed |
description | CONTEXT: Atorvastatin (ATV) and QiShenYiQi pills (QSYQ), a Chinese patent medicine, are often co-prescribed to Chinese cardiovascular patients. The effects of QSYQ on the pharmacokinetics of ATV have not been studied. OBJECTIVE: We investigated the influence of QSYQ on the pharmacokinetics of ATV and its metabolites upon oral or intravenous administration of ATV to rats. MATERIALS AND METHODS: Sprague-Dawley rats (n = 5/group) were pre-treated with oral QSYQ (675 mg/kg) or vehicle control for 7 days and then orally administrated ATV (10 mg/kg) or intravenously administrated ATV (2 mg/kg). Serum concentrations of ATV and metabolites were determined by ultra-high performance liquid chromatography tandem mass spectrometry. Expression of metabolic enzymes and transporters in jejunum and ileum were measured by quantitative real-time PCR and Western blot. RESULTS: QSYQ resulted in an increase of AUC(0-12 h) of ATV from 226.67 ± 42.11 to 408.70 ± 161.75 ng/mL/h and of C(max) of ATV from 101.46 ± 26.18 to 198.00 ± 51.69 ng/mL and in an increased of para-hydroxy atorvastatin from 9.07 ± 6.20 to 23.10 ± 8.70 ng/mL in rats administered ATV orally. No change was observed in rats treated intravenously. The expression of multidrug resistance-associated protein 2 mRNA and protein decreased in ileum, and the mRNA of P-glycoprotein decreased in jejunum, though no change in protein expression was found. DISCUSSION AND CONCLUSIONS: QSYQ increased bioavailability of ATV administered orally through inhibiting the expression of Mrp2 in ileum. Clinicians should pay close attention to potential drug-drug interactions between ATV and QSYQ. |
format | Online Article Text |
id | pubmed-8745373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-87453732022-01-11 QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats Ding, Congyang Li, Yajing Li, Xiao Meng, Lu Fu, Ran Wang, Xiaonan Li, Ying Ma, Yinling Dong, Zhanjun Pharm Biol Research Article CONTEXT: Atorvastatin (ATV) and QiShenYiQi pills (QSYQ), a Chinese patent medicine, are often co-prescribed to Chinese cardiovascular patients. The effects of QSYQ on the pharmacokinetics of ATV have not been studied. OBJECTIVE: We investigated the influence of QSYQ on the pharmacokinetics of ATV and its metabolites upon oral or intravenous administration of ATV to rats. MATERIALS AND METHODS: Sprague-Dawley rats (n = 5/group) were pre-treated with oral QSYQ (675 mg/kg) or vehicle control for 7 days and then orally administrated ATV (10 mg/kg) or intravenously administrated ATV (2 mg/kg). Serum concentrations of ATV and metabolites were determined by ultra-high performance liquid chromatography tandem mass spectrometry. Expression of metabolic enzymes and transporters in jejunum and ileum were measured by quantitative real-time PCR and Western blot. RESULTS: QSYQ resulted in an increase of AUC(0-12 h) of ATV from 226.67 ± 42.11 to 408.70 ± 161.75 ng/mL/h and of C(max) of ATV from 101.46 ± 26.18 to 198.00 ± 51.69 ng/mL and in an increased of para-hydroxy atorvastatin from 9.07 ± 6.20 to 23.10 ± 8.70 ng/mL in rats administered ATV orally. No change was observed in rats treated intravenously. The expression of multidrug resistance-associated protein 2 mRNA and protein decreased in ileum, and the mRNA of P-glycoprotein decreased in jejunum, though no change in protein expression was found. DISCUSSION AND CONCLUSIONS: QSYQ increased bioavailability of ATV administered orally through inhibiting the expression of Mrp2 in ileum. Clinicians should pay close attention to potential drug-drug interactions between ATV and QSYQ. Taylor & Francis 2022-01-08 /pmc/articles/PMC8745373/ /pubmed/35001796 http://dx.doi.org/10.1080/13880209.2021.2021949 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ding, Congyang Li, Yajing Li, Xiao Meng, Lu Fu, Ran Wang, Xiaonan Li, Ying Ma, Yinling Dong, Zhanjun QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats |
title | QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats |
title_full | QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats |
title_fullStr | QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats |
title_full_unstemmed | QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats |
title_short | QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats |
title_sort | qishenyiqi pills, a chinese patent medicine, increase bioavailability of atorvastatin by inhibiting mrp2 expression in rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745373/ https://www.ncbi.nlm.nih.gov/pubmed/35001796 http://dx.doi.org/10.1080/13880209.2021.2021949 |
work_keys_str_mv | AT dingcongyang qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats AT liyajing qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats AT lixiao qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats AT menglu qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats AT furan qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats AT wangxiaonan qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats AT liying qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats AT mayinling qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats AT dongzhanjun qishenyiqipillsachinesepatentmedicineincreasebioavailabilityofatorvastatinbyinhibitingmrp2expressioninrats |